Although new methods for CC suppression are currently under investigation, such as sulfatase 2 monoclonal antibody [9], the discovery of additional therapeutic targets remains urgently necessary to treat patients with CC across all onset sites. The gene discussed is SULF2; the disease is cholangiocarcinoma.